Biography
I am a pulmonologist with a strong interest in tuberculosis (TB), which has been my focus for the past five years following my fellowship in pulmonology. Recently, I had the opportunity to attend a course on ending TB at the Research Institute of Tuberculosis in Japan. This experience deeply inspired me, and I was impressed by Japan's strategies for combating TB. My ambition is now heightened to contribute significantly to ending TB in Thailand, drawing inspiration from the effective approaches I learned in Japan.
Key Impacts
NAT2 genotypes and clinical characteristics associated with liver injury in people with TB treated with first-line anti-TB therapy
This study shows NAT2 slow acetylator genotypes and chronic hepatitis C infection as key risk factors for AT-DILI in tuberculosis patients treated with first-line anti-tuberculosis drugs. These findings emphasize the importance of genetic screening and close monitoring of liver function in high-risk populations to reduce treatment interruptions and improve therapeutic outcomes
Source: Conference 2024